Add Company
Join Now

KaliVir Immunotherapeutics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • KaliVir Immunotherapeutics's estimated annual revenue is currently $4.3M per year.(i)
  • KaliVir Immunotherapeutics's estimated revenue per employee is $100,500

Employee Data

  • KaliVir Immunotherapeutics has 43 Employees.(i)
  • KaliVir Immunotherapeutics grew their employee count by 54% last year.

KaliVir Immunotherapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
ControllerReveal Email/Phone
3
SVP Clinical OperationsReveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
Associate Director, Process DevelopmentReveal Email/Phone
6
Director Operations, GMP ManufacturingReveal Email/Phone
7
Director Technical OperationsReveal Email/Phone
8
Director ImmunologyReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
Senior Manager Quality ControlReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is KaliVir Immunotherapeutics?

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.

keywords:N/A

N/A

Total Funding

43

Number of Employees

$4.3M

Revenue (est)

54%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.5M432%N/A
#2
$7.6M430%N/A
#3
$10.6M43-36%N/A
#4
$3.5M432%N/A
#5
$10M43-12%N/A